Expressive Writing for Cancer Survivors

NCT04171609 | Completed

• 1 other identifier: Pro00101278
• Study Type: interventional
• Target: 14
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to determine whether a 1-day expressive writing intervention for adult cancer survivors improves resilience scores as measured by the Connor-Davidson Resilience Scale (CD-RISC).

Conditions

Cancer Survivors

Outcome Measures

Primary Outcomes (1)

• Change in resilience as measured by the Connor-Davidson Resilience Scale

  This 25-item scale addresses resilience, and has been studied in a variety of populations. Resilience is considered as the capacity to overcome adversity.

  Baseline, 6 months

Secondary Outcomes (5)

• Post-writing survey

  1 day (collected during the 1-day intervention)

• Change in quality of life as measured by the Quality of Life Patient/Cancer Survivor Version (QOL-CSV)

  Baseline, 6 months

• Change in perceived stress as measured by Perceived Stress Scale (PSS-10)

  Baseline, 6 months

• Change in depression as measured by Center for Epidemiological Studies Depression Scale Revised (CESD-R)

  Baseline, 6 months

• Qualitative follow-up questionnaire

  6 months

Study Arms (1)

Cancer survivors

EXPERIMENTAL

Adult survivors of any kind of cancer (except for minor skin cancer) are eligible to participate

Behavioral: Expressive writing

Interventions

Expressive writing BEHAVIORAL

During this daylong expressive writing workshop intervention, the writing instructor coached participants through a series of simple writing exercises. Participation required neither any prior writing experience, nor any desire to become a writer. The practices cultivate natural abilities to express the ideas that define who you are and how you experience your life.

Cancer survivors

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Have ever received a cancer diagnosis
• Have completed cancer treatment (e.g., surgery, radiation, or chemotherapy)
• Are able to speak, read, write, and understand English
• Are cognitively able to provide consent
• Are able to travel to Durham to participate in the 1-day writing intervention

You may not qualify if:

• Cancer diagnosis was skin cancer that did not require additional treatment after surgical removal

Sponsors & Collaborators

• Duke University: lead

Study Sites (1)

Duke Integrative Medicine

Durham, North Carolina, 27705, United States

Location

Study Officials

• Oliver Glass, PhD

  Duke University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 19, 2019
• First Posted: November 21, 2019
• Study Start: July 19, 2019
• Primary Completion: May 14, 2020
• Study Completion: May 14, 2020
• Last Updated: August 25, 2020

Record last verified: 2019-11

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)